Skip to main content
Premium Trial:

Request an Annual Quote

FDA Grants EUA to Enzo Biochem Sample Collection Kit for COVID-19 Testing

NEW YORK – Enzo Biochem said on Wednesday that the US Food and Drug Administration has granted Emergency Use Authorization to the company's Ampicollect Sample Collection kit, making it available for COVID-19 testing protocols in the US.

The kit has been shown to meet the FDA's standards during the pandemic for viral transport media, Enzo said. It can be used with Enzo's GenFlex molecular diagnostic platform as well as other PCR-based molecular diagnostic or antigen-based testing platforms that require the collection of upper respiratory specimens.

"Emergency Use Authorization for our Ampicollect Sample Collection kit is another reflection of the strength of our open platform approach and integrated model at work," Enzo CEO Elazar Rabbani said in a statement. "By internally developing and manufacturing key aspects of diagnostic testing technologies, we have successfully overcome the systemic challenges that affected this sector during the COVID-19 pandemic, including supply shortages and high costs."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.